{"title":"福辛普利及其类似物的体外筛选与对接研究","authors":"S. Kini, J. Chaudhary, S. Arora","doi":"10.1109/ICBPE.2009.5384099","DOIUrl":null,"url":null,"abstract":"Hypertension is the most common cardiovascular disease. The prevalence of hypertension increases with advancing age; for example, about 50% of people between the ages of 60 and 69 years old have hypertension, and the prevalence is further increased beyond age of 70. Many angiotensin converting enzyme (ACE) inhibitors are known to be useful in the treatment of hypertension.","PeriodicalId":384086,"journal":{"name":"2009 International Conference on Biomedical and Pharmaceutical Engineering","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In-vitro screening and docking study of fosinopril and its analogs\",\"authors\":\"S. Kini, J. Chaudhary, S. Arora\",\"doi\":\"10.1109/ICBPE.2009.5384099\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hypertension is the most common cardiovascular disease. The prevalence of hypertension increases with advancing age; for example, about 50% of people between the ages of 60 and 69 years old have hypertension, and the prevalence is further increased beyond age of 70. Many angiotensin converting enzyme (ACE) inhibitors are known to be useful in the treatment of hypertension.\",\"PeriodicalId\":384086,\"journal\":{\"name\":\"2009 International Conference on Biomedical and Pharmaceutical Engineering\",\"volume\":\"11 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"2009 International Conference on Biomedical and Pharmaceutical Engineering\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1109/ICBPE.2009.5384099\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"2009 International Conference on Biomedical and Pharmaceutical Engineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1109/ICBPE.2009.5384099","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
In-vitro screening and docking study of fosinopril and its analogs
Hypertension is the most common cardiovascular disease. The prevalence of hypertension increases with advancing age; for example, about 50% of people between the ages of 60 and 69 years old have hypertension, and the prevalence is further increased beyond age of 70. Many angiotensin converting enzyme (ACE) inhibitors are known to be useful in the treatment of hypertension.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
